Aside from finding the vaccine 79% effective, the preliminary results indicated the vaccine was even more effective in study subjects ages 65 years and older, and the shot was safe.
The late-stage, or Phase 3, trial had 32,449 subjects in the U.S., Peru and Chile. About 20% of them were 65 years or older.
The fuller data showed the vaccine to be 85% effective in the older age group. Older adults are considered more vulnerable to serious Covid-19, making them a high-priority group in vaccinations globally.
Though AstraZeneca’s latest release involved more cases, the company’s analysis might still be incomplete. AstraZeneca said it was reviewing an additional 14 cases to see if they should be added to the final tally.
Author(s): Jenny Strasburg, Joseph Walker
Publication Date: 24 March 2021
Publication Site: Wall Street Journal